샘플 요청 목록

 카트 문의
시장보고서
상품코드
1795179

세계의 여행용 백신 시장

Travel Vaccines
발행일: | 리서치사: Market Glass, Inc. (Formerly Global Industry Analysts, Inc.) | 페이지 정보: 영문 281 Pages | 배송안내 : 1-2일 (영업일 기준)

    
    
    



※ 본 상품은 영문 자료로 한글과 영문 목차에 불일치하는 내용이 있을 경우 영문을 우선합니다. 정확한 검토를 위해 영문 목차를 참고해주시기 바랍니다.

여행용 백신 세계 시장은 2030년까지 188억 달러에 달할 전망

2024년에 132억 달러로 추정되는 여행용 백신 세계 시장은 2024-2030년 분석 기간에 CAGR 6.0%로 성장하여 2030년에는 188억 달러에 달할 것으로 예측됩니다. 이 보고서에서 분석한 부문 중 하나인 인플루엔자 백신은 CAGR 5.5%를 기록하며 분석 기간 종료시에는 94억 달러에 달할 것으로 예측됩니다. 디프테리아 백신 분야의 성장률은 분석 기간 동안 CAGR 4.9%로 추정됩니다.

미국 시장은 36억 달러, 중국은 CAGR 9.4%로 성장할 것으로 예측

미국의 여행용 백신 시장은 2024년에는 36억 달러에 달할 것으로 추정됩니다. 세계 2위 경제 대국인 중국은 2030년까지 38억 달러의 시장 규모에 달할 것으로 예측되며, 분석 기간인 2024-2030년 CAGR은 9.4%를 기록할 것으로 예상됩니다. 기타 주목할 만한 지역별 시장으로는 일본과 캐나다가 있고, 분석 기간 동안 CAGR은 각각 3.0%와 5.9%로 예측됩니다. 유럽에서는 독일이 CAGR 3.9%로 성장할 것으로 예측됩니다.

세계의 여행용 백신 시장 - 주요 동향과 촉진요인 정리

여행용 백신이 국제 이동의 필수 조건이 되고 있는 이유는 무엇일까?

여행용 백신은 국제 이동이 쉬워질수록 감염병 전파 위험이 높아지는 세계화 시대에 중요한 안전장치로 부상하고 있습니다. 황열병, A형 및 B형 간염, 장티푸스, 광견병, 콜레라, 일본뇌염 예방접종은 특정 국가를 방문하는 여행객에게 권장될 뿐만 아니라 종종 의무적으로 접종해야 합니다. 이러한 예방접종은 여행자와 수용국 국민 모두를 보호하고, 전 세계 질병을 억제하는 데 필수적인 공중보건 수단으로 작용하고 있습니다.

COVID-19 팬데믹 이후 인식이 높아지면서 여행 전 건강검진 및 예방접종 계획의 이행률이 크게 증가했습니다. 각국 정부가 국경 간 건강 검진을 강화함에 따라 여행자들은 예방접종 일정을 준수하게 되었습니다. 다국적 보건 기관과 여행 의료 클리닉은 가이드라인을 강화하고 있으며, 특히 아프리카, 아시아, 라틴아메리카의 고위험 지역에서는 여행자의 준비 태세를 검증하기 위한 디지털 백신 인증 시스템을 도입하고 있습니다.

기술 및 제제의 발전은 백신 접종을 어떻게 촉진하고 있는가?

mRNA 플랫폼, 내열성 제제, 혼합 백신 등 백신학 분야에서는 큰 기술 혁신이 진행되고 있습니다. 이러한 발전은 콜드체인에 대한 의존도를 줄이고, 보관 기간을 연장하며, 투여 일정을 간소화합니다. 일부 여행용 백신은 1회 접종으로 충분하거나 경구투여가 가능한 백신도 있어 순응도 및 접근성이 향상되고 있습니다.

또 다른 주요 개발은 전자의무기록과 모바일 앱의 통합입니다. 이 앱들은 알림을 자동화하고, 여행지별 위험에 기반한 가이드를 제공합니다. 클리닉은 맞춤형 백신 계획과 디지털 인증서를 번들로 제공하는 패키지를 제공합니다. 또한, 프리필드 시린지, 마이크로니들 패치, 비강용 제제는 특히 소아 및 노인층에 대한 투약의 안전성과 효율성을 높이고 있습니다.

수요를 촉진하는 여행자 계층과 목적지는?

고위험 지역 여행자, 인도주의 활동가, 유학생, 출장자가 여행용 백신의 주요 소비자입니다. 생태관광, 농촌관광, 모험여행이 급증하면서 매개체 감염병과 인수공통전염병에 노출될 기회가 많아져 백신 접종에 대한 필요성이 높아지고 있습니다. 또한, 신흥 시장으로의 기업 출장 및 세계 공급망 확대로 인해 기업이 자금을 지원하는 예방접종 프로그램이 증가하고 있습니다.

또한, 디지털 노마드, 선교사, 해외 주재원 등 장기 또는 여러 차례의 부스터 접종이 필요한 비전통적 여행자의 수요도 증가하고 있습니다. 여행지 특유의 건강 위험과 전염병 경보로 인해 백신 요구 사항이 자주 변경되기 때문에 여행 클리닉은 막판에 수요가 급증합니다. 또한, 국가적 의무와 건강 권고사항은 백신의 가용성과 여행자의 준수 여부에 지속적으로 영향을 미치고 있습니다.

여행 백신 시장의 성장은 몇 가지 요인에 의해 주도됩니다...

전 세계 여행자 수 증가, 지역 특유의 질병 위험에 대한 인식 증가, 국경 간 건강 프로토콜의 강화 등이 성장의 주요 요인입니다. mRNA, 접합체, 재조합 기술을 포함한 백신 플랫폼의 발전은 여행용 백신의 가용성과 효능을 높이고 있습니다. 모험, 생태관광, 오프그리드 여행의 증가로 인해 병원체 노출이 높은 지역으로 여행하는 여행객이 증가함에 따라 선제적 예방접종이 필요하게 되었습니다. 디지털 헬스 툴과 모바일 백신 패스포트 시스템은 여행 전 백신 접종을 간소화하고 보다 일관성 있는 접종을 장려하고 있습니다. 또한, 정부와 국제보건기구의 제도적 지원과 노동력 보호에 대한 민간 부문의 노력이 시장의 성장세를 더욱 가속화하고 있습니다.

부문

질병 유형(인플루엔자 백신, 디프테리아 백신, 간염 백신, 장티푸스·기타 백신), 최종사용자(성인, 소아)

조사 대상 기업 사례

  • Abbott Laboratories
  • ALK-Abello A/S
  • AstraZeneca PLC
  • Bavarian Nordic A/S
  • CSL Limited
  • F.?Hoffmann-La Roche AG
  • GlaxoSmithKline plc
  • Janssen Pharmaceuticals(J&J)
  • Merck & Co., Inc.
  • Moderna Inc.(if included)
  • Novartis AG
  • Novavax, Inc.
  • Pfizer Inc.
  • Qiagen NV
  • Sanofi S.A.
  • Valneva SE

AI 통합

우리는 검증된 전문가 컨텐츠와 AI 툴을 통해 시장 정보와 경쟁 정보를 혁신하고 있습니다.

Global Industry Analysts는 LLM 및 업계 고유의 SLM을 조회하는 일반적인 규범을 따르는 대신 비디오 기록, 블로그, 검색 엔진 조사, 방대한 양의 기업, 제품/서비스, 시장 데이터 등 세계 전문가로부터 수집한 컨텐츠 리포지토리를 구축했습니다.

관세 영향 계수

Global Industry Analysts는 본사 소재지, 제조거점, 수출입(완제품 및 OEM)을 기준으로 기업의 경쟁력 변화를 예측하고 있습니다. 이러한 복잡하고 다면적인 시장 역학은 매출원가(COGS) 증가, 수익성 하락, 공급망 재편 등 미시적, 거시적 시장 역학 중에서도 특히 경쟁사들에게 영향을 미칠 것으로 예상됩니다.

목차

제1장 조사 방법

제2장 주요 요약

  • 시장 개요
  • 주요 기업
  • 시장 동향과 촉진요인
  • 세계 시장 전망

제3장 시장 분석

  • 미국
  • 캐나다
  • 일본
  • 중국
  • 유럽
  • 프랑스
  • 독일
  • 이탈리아
  • 영국
  • 스페인
  • 러시아
  • 기타 유럽
  • 아시아태평양
  • 호주
  • 인도
  • 한국
  • 기타 아시아태평양
  • 라틴아메리카
  • 아르헨티나
  • 브라질
  • 멕시코
  • 기타 라틴아메리카
  • 중동
  • 이란
  • 이스라엘
  • 사우디아라비아
  • 아랍에미리트
  • 기타 중동
  • 아프리카

제4장 경쟁

KSM 25.08.28

Global Travel Vaccines Market to Reach US$18.8 Billion by 2030

The global market for Travel Vaccines estimated at US$13.2 Billion in the year 2024, is expected to reach US$18.8 Billion by 2030, growing at a CAGR of 6.0% over the analysis period 2024-2030. Influenza Vaccines, one of the segments analyzed in the report, is expected to record a 5.5% CAGR and reach US$9.4 Billion by the end of the analysis period. Growth in the Diphtheria Vaccines segment is estimated at 4.9% CAGR over the analysis period.

The U.S. Market is Estimated at US$3.6 Billion While China is Forecast to Grow at 9.4% CAGR

The Travel Vaccines market in the U.S. is estimated at US$3.6 Billion in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$3.8 Billion by the year 2030 trailing a CAGR of 9.4% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 3.0% and 5.9% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 3.9% CAGR.

Global Travel Vaccines Market - Key Trends & Drivers Summarized

Why Are Travel Vaccines Becoming a Prerequisite for International Mobility?

Travel vaccines have emerged as vital safeguards in a globalized world, where the ease of international movement also raises the risk of infectious disease transmission. Vaccines for yellow fever, hepatitis A and B, typhoid, rabies, cholera, and Japanese encephalitis are not only recommended but often mandatory for travelers visiting specific countries. These immunizations protect travelers and host populations alike, acting as essential public health tools in global disease containment.

Heightened awareness following the COVID-19 pandemic has significantly increased the uptake of pre-travel medical consultations and vaccination plans. As governments tighten cross-border health checks, travelers are more willing to comply with immunization schedules. Multilateral health bodies and travel medicine clinics are reinforcing guidelines, and digital vaccine certification systems have been deployed to validate traveler readiness, particularly in higher-risk regions of Africa, Asia, and Latin America.

How Are Technological and Formulation Advances Enhancing Vaccine Uptake?

The field of vaccinology is undergoing significant innovation, with mRNA platforms, thermostable formulations, and combination vaccines being tailored for travel use. These advances are reducing cold chain dependency, extending shelf life, and simplifying dosage schedules-key benefits for last-minute or remote-area travelers. Some travel vaccines now require just one dose or offer oral options, improving compliance and accessibility.

Another key development is the integration of electronic health records and mobile apps that automate reminders and provide guidance based on destination-specific risks. Clinics are offering bundled packages with tailored vaccine plans and digital certificates. Additionally, prefilled syringes, microneedle patches, and intranasal formulations are enhancing administration safety and efficiency, particularly for pediatric and elderly populations.

Which Traveler Segments and Destinations Are Fueling Demand?

Tourists, humanitarian workers, international students, and business travelers to high-risk regions are primary consumers of travel vaccines. The surge in eco-tourism, rural tourism, and adventure travel increases exposure to vector-borne diseases and zoonoses, driving vaccination needs. Additionally, corporate travel to emerging markets and global supply chain expansion has led to a rise in enterprise-funded immunization programs.

The demand is also rising in non-traditional traveler categories such as digital nomads, missionaries, and expatriates, who require long-term or multiple booster doses. Destination-specific health risks and outbreak alerts frequently alter vaccine requirements, prompting last-minute surges in demand at travel clinics. Furthermore, national mandates and health advisories continue to influence both vaccine availability and traveler compliance.

The Growth in the Travel Vaccines Market Is Driven by Several Factors…

Expansion in global travel volumes, heightened awareness of region-specific disease risks, and stricter cross-border health protocols are key growth enablers. Advancements in vaccine platforms-including mRNA, conjugate, and recombinant technologies-are increasing the availability and efficacy of travel vaccines. The rise in adventure, eco-tourism, and off-grid travel is pushing more travelers into regions with higher pathogen exposure, necessitating preemptive immunization. Digital health tools and mobile vaccine passport systems are streamlining pre-travel compliance, encouraging more consistent uptake. Additionally, institutional support from governments and global health organizations, alongside private sector initiatives in workforce protection, are further accelerating market momentum.

SCOPE OF STUDY:

The report analyzes the Travel Vaccines market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:

Disease Type (Influenza Vaccines, Diphtheria Vaccines, Hepatitis Vaccines, Typhoid & Other Vaccines); End-Use (Adult End-Use, Pediatric End-Use)

Geographic Regions/Countries:

World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.

Select Competitors (Total 44 Featured) -

  • Abbott Laboratories
  • ALK-Abello A/S
  • AstraZeneca PLC
  • Bavarian Nordic A/S
  • CSL Limited
  • F.?Hoffmann-La Roche AG
  • GlaxoSmithKline plc
  • Janssen Pharmaceuticals (J&J)
  • Merck & Co., Inc.
  • Moderna Inc. (if included)
  • Novartis AG
  • Novavax, Inc.
  • Pfizer Inc.
  • Qiagen NV
  • Sanofi S.A.
  • Valneva SE

AI INTEGRATIONS

We're transforming market and competitive intelligence with validated expert content and AI tools.

Instead of following the general norm of querying LLMs and Industry-specific SLMs, we built repositories of content curated from domain experts worldwide including video transcripts, blogs, search engines research, and massive amounts of enterprise, product/service, and market data.

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by increasing the Cost of Goods Sold (COGS), reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

  • 1. MARKET OVERVIEW
    • Influencer Market Insights
    • World Market Trajectories
    • Tariff Impact on Global Supply Chain Patterns
    • Travel Vaccines - Global Key Competitors Percentage Market Share in 2025 (E)
    • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2025 (E)
  • 2. FOCUS ON SELECT PLAYERS
  • 3. MARKET TRENDS & DRIVERS
    • Rising International Travel and Cross-Border Movement Drives Demand for Pre-Travel Vaccinations
    • Increased Awareness of Endemic Disease Risks in Emerging Destinations Fuels Preventive Vaccine Uptake
    • Growth in Business, Educational, and Medical Tourism Supports Volume Demand
    • Expanded Inclusion of Yellow Fever, Typhoid, Hepatitis, and Meningococcal Vaccines in Pre-Travel Protocols
    • Regulatory Requirements for Entry Into Certain Countries Drive Compliance-Driven Vaccine Demand
    • Use of Combination and Single-Dose Formulations Improves Convenience and Reduces Missed Doses
    • Growth in Private Clinics and Travel Health Centers Enhances Access to Targeted Immunizations
    • Increased Awareness Campaigns by Health Ministries and Airlines Support Preventive Measures
    • Seasonal Travel Peaks Correlate With Vaccine Appointment Upticks in Urban Markets
    • Availability of Pre-Filled Syringes and Multi-Dose Packs Improves Distribution Efficiency
    • Travel Health App Integrations Support Vaccine Reminders and Record Management
    • Adoption in Backpacking, Volunteer, and High-Risk Travel Segments Sustains Niche Growth
  • 4. GLOBAL MARKET PERSPECTIVE
    • TABLE 1: World Travel Vaccines Market Analysis of Annual Sales in US$ Million for Years 2014 through 2030
    • TABLE 2: World Recent Past, Current & Future Analysis for Travel Vaccines by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 3: World Historic Review for Travel Vaccines by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 4: World 16-Year Perspective for Travel Vaccines by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2014, 2025 & 2030
    • TABLE 5: World Recent Past, Current & Future Analysis for Influenza Vaccines by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 6: World Historic Review for Influenza Vaccines by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 7: World 16-Year Perspective for Influenza Vaccines by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 8: World Recent Past, Current & Future Analysis for Diphtheria Vaccines by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 9: World Historic Review for Diphtheria Vaccines by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 10: World 16-Year Perspective for Diphtheria Vaccines by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 11: World Recent Past, Current & Future Analysis for Hepatitis Vaccines by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 12: World Historic Review for Hepatitis Vaccines by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 13: World 16-Year Perspective for Hepatitis Vaccines by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 14: World Recent Past, Current & Future Analysis for Typhoid & Other Vaccines by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 15: World Historic Review for Typhoid & Other Vaccines by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 16: World 16-Year Perspective for Typhoid & Other Vaccines by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 17: World Recent Past, Current & Future Analysis for Adult End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 18: World Historic Review for Adult End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 19: World 16-Year Perspective for Adult End-Use by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 20: World Recent Past, Current & Future Analysis for Pediatric End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 21: World Historic Review for Pediatric End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 22: World 16-Year Perspective for Pediatric End-Use by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030

III. MARKET ANALYSIS

  • UNITED STATES
    • Travel Vaccines Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2025 (E)
    • TABLE 23: USA Recent Past, Current & Future Analysis for Travel Vaccines by Disease Type - Influenza Vaccines, Diphtheria Vaccines, Hepatitis Vaccines and Typhoid & Other Vaccines - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 24: USA Historic Review for Travel Vaccines by Disease Type - Influenza Vaccines, Diphtheria Vaccines, Hepatitis Vaccines and Typhoid & Other Vaccines Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 25: USA 16-Year Perspective for Travel Vaccines by Disease Type - Percentage Breakdown of Value Sales for Influenza Vaccines, Diphtheria Vaccines, Hepatitis Vaccines and Typhoid & Other Vaccines for the Years 2014, 2025 & 2030
    • TABLE 26: USA Recent Past, Current & Future Analysis for Travel Vaccines by End-Use - Adult End-Use and Pediatric End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 27: USA Historic Review for Travel Vaccines by End-Use - Adult End-Use and Pediatric End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 28: USA 16-Year Perspective for Travel Vaccines by End-Use - Percentage Breakdown of Value Sales for Adult End-Use and Pediatric End-Use for the Years 2014, 2025 & 2030
  • CANADA
    • TABLE 29: Canada Recent Past, Current & Future Analysis for Travel Vaccines by Disease Type - Influenza Vaccines, Diphtheria Vaccines, Hepatitis Vaccines and Typhoid & Other Vaccines - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 30: Canada Historic Review for Travel Vaccines by Disease Type - Influenza Vaccines, Diphtheria Vaccines, Hepatitis Vaccines and Typhoid & Other Vaccines Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 31: Canada 16-Year Perspective for Travel Vaccines by Disease Type - Percentage Breakdown of Value Sales for Influenza Vaccines, Diphtheria Vaccines, Hepatitis Vaccines and Typhoid & Other Vaccines for the Years 2014, 2025 & 2030
    • TABLE 32: Canada Recent Past, Current & Future Analysis for Travel Vaccines by End-Use - Adult End-Use and Pediatric End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 33: Canada Historic Review for Travel Vaccines by End-Use - Adult End-Use and Pediatric End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 34: Canada 16-Year Perspective for Travel Vaccines by End-Use - Percentage Breakdown of Value Sales for Adult End-Use and Pediatric End-Use for the Years 2014, 2025 & 2030
  • JAPAN
    • Travel Vaccines Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2025 (E)
    • TABLE 35: Japan Recent Past, Current & Future Analysis for Travel Vaccines by Disease Type - Influenza Vaccines, Diphtheria Vaccines, Hepatitis Vaccines and Typhoid & Other Vaccines - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 36: Japan Historic Review for Travel Vaccines by Disease Type - Influenza Vaccines, Diphtheria Vaccines, Hepatitis Vaccines and Typhoid & Other Vaccines Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 37: Japan 16-Year Perspective for Travel Vaccines by Disease Type - Percentage Breakdown of Value Sales for Influenza Vaccines, Diphtheria Vaccines, Hepatitis Vaccines and Typhoid & Other Vaccines for the Years 2014, 2025 & 2030
    • TABLE 38: Japan Recent Past, Current & Future Analysis for Travel Vaccines by End-Use - Adult End-Use and Pediatric End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 39: Japan Historic Review for Travel Vaccines by End-Use - Adult End-Use and Pediatric End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 40: Japan 16-Year Perspective for Travel Vaccines by End-Use - Percentage Breakdown of Value Sales for Adult End-Use and Pediatric End-Use for the Years 2014, 2025 & 2030
  • CHINA
    • Travel Vaccines Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2025 (E)
    • TABLE 41: China Recent Past, Current & Future Analysis for Travel Vaccines by Disease Type - Influenza Vaccines, Diphtheria Vaccines, Hepatitis Vaccines and Typhoid & Other Vaccines - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 42: China Historic Review for Travel Vaccines by Disease Type - Influenza Vaccines, Diphtheria Vaccines, Hepatitis Vaccines and Typhoid & Other Vaccines Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 43: China 16-Year Perspective for Travel Vaccines by Disease Type - Percentage Breakdown of Value Sales for Influenza Vaccines, Diphtheria Vaccines, Hepatitis Vaccines and Typhoid & Other Vaccines for the Years 2014, 2025 & 2030
    • TABLE 44: China Recent Past, Current & Future Analysis for Travel Vaccines by End-Use - Adult End-Use and Pediatric End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 45: China Historic Review for Travel Vaccines by End-Use - Adult End-Use and Pediatric End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 46: China 16-Year Perspective for Travel Vaccines by End-Use - Percentage Breakdown of Value Sales for Adult End-Use and Pediatric End-Use for the Years 2014, 2025 & 2030
  • EUROPE
    • Travel Vaccines Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2025 (E)
    • TABLE 47: Europe Recent Past, Current & Future Analysis for Travel Vaccines by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 48: Europe Historic Review for Travel Vaccines by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 49: Europe 16-Year Perspective for Travel Vaccines by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2014, 2025 & 2030
    • TABLE 50: Europe Recent Past, Current & Future Analysis for Travel Vaccines by Disease Type - Influenza Vaccines, Diphtheria Vaccines, Hepatitis Vaccines and Typhoid & Other Vaccines - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 51: Europe Historic Review for Travel Vaccines by Disease Type - Influenza Vaccines, Diphtheria Vaccines, Hepatitis Vaccines and Typhoid & Other Vaccines Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 52: Europe 16-Year Perspective for Travel Vaccines by Disease Type - Percentage Breakdown of Value Sales for Influenza Vaccines, Diphtheria Vaccines, Hepatitis Vaccines and Typhoid & Other Vaccines for the Years 2014, 2025 & 2030
    • TABLE 53: Europe Recent Past, Current & Future Analysis for Travel Vaccines by End-Use - Adult End-Use and Pediatric End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 54: Europe Historic Review for Travel Vaccines by End-Use - Adult End-Use and Pediatric End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 55: Europe 16-Year Perspective for Travel Vaccines by End-Use - Percentage Breakdown of Value Sales for Adult End-Use and Pediatric End-Use for the Years 2014, 2025 & 2030
  • FRANCE
    • Travel Vaccines Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2025 (E)
    • TABLE 56: France Recent Past, Current & Future Analysis for Travel Vaccines by Disease Type - Influenza Vaccines, Diphtheria Vaccines, Hepatitis Vaccines and Typhoid & Other Vaccines - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 57: France Historic Review for Travel Vaccines by Disease Type - Influenza Vaccines, Diphtheria Vaccines, Hepatitis Vaccines and Typhoid & Other Vaccines Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 58: France 16-Year Perspective for Travel Vaccines by Disease Type - Percentage Breakdown of Value Sales for Influenza Vaccines, Diphtheria Vaccines, Hepatitis Vaccines and Typhoid & Other Vaccines for the Years 2014, 2025 & 2030
    • TABLE 59: France Recent Past, Current & Future Analysis for Travel Vaccines by End-Use - Adult End-Use and Pediatric End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 60: France Historic Review for Travel Vaccines by End-Use - Adult End-Use and Pediatric End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 61: France 16-Year Perspective for Travel Vaccines by End-Use - Percentage Breakdown of Value Sales for Adult End-Use and Pediatric End-Use for the Years 2014, 2025 & 2030
  • GERMANY
    • Travel Vaccines Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2025 (E)
    • TABLE 62: Germany Recent Past, Current & Future Analysis for Travel Vaccines by Disease Type - Influenza Vaccines, Diphtheria Vaccines, Hepatitis Vaccines and Typhoid & Other Vaccines - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 63: Germany Historic Review for Travel Vaccines by Disease Type - Influenza Vaccines, Diphtheria Vaccines, Hepatitis Vaccines and Typhoid & Other Vaccines Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 64: Germany 16-Year Perspective for Travel Vaccines by Disease Type - Percentage Breakdown of Value Sales for Influenza Vaccines, Diphtheria Vaccines, Hepatitis Vaccines and Typhoid & Other Vaccines for the Years 2014, 2025 & 2030
    • TABLE 65: Germany Recent Past, Current & Future Analysis for Travel Vaccines by End-Use - Adult End-Use and Pediatric End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 66: Germany Historic Review for Travel Vaccines by End-Use - Adult End-Use and Pediatric End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 67: Germany 16-Year Perspective for Travel Vaccines by End-Use - Percentage Breakdown of Value Sales for Adult End-Use and Pediatric End-Use for the Years 2014, 2025 & 2030
  • ITALY
    • TABLE 68: Italy Recent Past, Current & Future Analysis for Travel Vaccines by Disease Type - Influenza Vaccines, Diphtheria Vaccines, Hepatitis Vaccines and Typhoid & Other Vaccines - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 69: Italy Historic Review for Travel Vaccines by Disease Type - Influenza Vaccines, Diphtheria Vaccines, Hepatitis Vaccines and Typhoid & Other Vaccines Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 70: Italy 16-Year Perspective for Travel Vaccines by Disease Type - Percentage Breakdown of Value Sales for Influenza Vaccines, Diphtheria Vaccines, Hepatitis Vaccines and Typhoid & Other Vaccines for the Years 2014, 2025 & 2030
    • TABLE 71: Italy Recent Past, Current & Future Analysis for Travel Vaccines by End-Use - Adult End-Use and Pediatric End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 72: Italy Historic Review for Travel Vaccines by End-Use - Adult End-Use and Pediatric End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 73: Italy 16-Year Perspective for Travel Vaccines by End-Use - Percentage Breakdown of Value Sales for Adult End-Use and Pediatric End-Use for the Years 2014, 2025 & 2030
  • UNITED KINGDOM
    • Travel Vaccines Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2025 (E)
    • TABLE 74: UK Recent Past, Current & Future Analysis for Travel Vaccines by Disease Type - Influenza Vaccines, Diphtheria Vaccines, Hepatitis Vaccines and Typhoid & Other Vaccines - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 75: UK Historic Review for Travel Vaccines by Disease Type - Influenza Vaccines, Diphtheria Vaccines, Hepatitis Vaccines and Typhoid & Other Vaccines Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 76: UK 16-Year Perspective for Travel Vaccines by Disease Type - Percentage Breakdown of Value Sales for Influenza Vaccines, Diphtheria Vaccines, Hepatitis Vaccines and Typhoid & Other Vaccines for the Years 2014, 2025 & 2030
    • TABLE 77: UK Recent Past, Current & Future Analysis for Travel Vaccines by End-Use - Adult End-Use and Pediatric End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 78: UK Historic Review for Travel Vaccines by End-Use - Adult End-Use and Pediatric End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 79: UK 16-Year Perspective for Travel Vaccines by End-Use - Percentage Breakdown of Value Sales for Adult End-Use and Pediatric End-Use for the Years 2014, 2025 & 2030
  • SPAIN
    • TABLE 80: Spain Recent Past, Current & Future Analysis for Travel Vaccines by Disease Type - Influenza Vaccines, Diphtheria Vaccines, Hepatitis Vaccines and Typhoid & Other Vaccines - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 81: Spain Historic Review for Travel Vaccines by Disease Type - Influenza Vaccines, Diphtheria Vaccines, Hepatitis Vaccines and Typhoid & Other Vaccines Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 82: Spain 16-Year Perspective for Travel Vaccines by Disease Type - Percentage Breakdown of Value Sales for Influenza Vaccines, Diphtheria Vaccines, Hepatitis Vaccines and Typhoid & Other Vaccines for the Years 2014, 2025 & 2030
    • TABLE 83: Spain Recent Past, Current & Future Analysis for Travel Vaccines by End-Use - Adult End-Use and Pediatric End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 84: Spain Historic Review for Travel Vaccines by End-Use - Adult End-Use and Pediatric End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 85: Spain 16-Year Perspective for Travel Vaccines by End-Use - Percentage Breakdown of Value Sales for Adult End-Use and Pediatric End-Use for the Years 2014, 2025 & 2030
  • RUSSIA
    • TABLE 86: Russia Recent Past, Current & Future Analysis for Travel Vaccines by Disease Type - Influenza Vaccines, Diphtheria Vaccines, Hepatitis Vaccines and Typhoid & Other Vaccines - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 87: Russia Historic Review for Travel Vaccines by Disease Type - Influenza Vaccines, Diphtheria Vaccines, Hepatitis Vaccines and Typhoid & Other Vaccines Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 88: Russia 16-Year Perspective for Travel Vaccines by Disease Type - Percentage Breakdown of Value Sales for Influenza Vaccines, Diphtheria Vaccines, Hepatitis Vaccines and Typhoid & Other Vaccines for the Years 2014, 2025 & 2030
    • TABLE 89: Russia Recent Past, Current & Future Analysis for Travel Vaccines by End-Use - Adult End-Use and Pediatric End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 90: Russia Historic Review for Travel Vaccines by End-Use - Adult End-Use and Pediatric End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 91: Russia 16-Year Perspective for Travel Vaccines by End-Use - Percentage Breakdown of Value Sales for Adult End-Use and Pediatric End-Use for the Years 2014, 2025 & 2030
  • REST OF EUROPE
    • TABLE 92: Rest of Europe Recent Past, Current & Future Analysis for Travel Vaccines by Disease Type - Influenza Vaccines, Diphtheria Vaccines, Hepatitis Vaccines and Typhoid & Other Vaccines - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 93: Rest of Europe Historic Review for Travel Vaccines by Disease Type - Influenza Vaccines, Diphtheria Vaccines, Hepatitis Vaccines and Typhoid & Other Vaccines Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 94: Rest of Europe 16-Year Perspective for Travel Vaccines by Disease Type - Percentage Breakdown of Value Sales for Influenza Vaccines, Diphtheria Vaccines, Hepatitis Vaccines and Typhoid & Other Vaccines for the Years 2014, 2025 & 2030
    • TABLE 95: Rest of Europe Recent Past, Current & Future Analysis for Travel Vaccines by End-Use - Adult End-Use and Pediatric End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 96: Rest of Europe Historic Review for Travel Vaccines by End-Use - Adult End-Use and Pediatric End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 97: Rest of Europe 16-Year Perspective for Travel Vaccines by End-Use - Percentage Breakdown of Value Sales for Adult End-Use and Pediatric End-Use for the Years 2014, 2025 & 2030
  • ASIA-PACIFIC
    • Travel Vaccines Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2025 (E)
    • TABLE 98: Asia-Pacific Recent Past, Current & Future Analysis for Travel Vaccines by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 99: Asia-Pacific Historic Review for Travel Vaccines by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 100: Asia-Pacific 16-Year Perspective for Travel Vaccines by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2014, 2025 & 2030
    • TABLE 101: Asia-Pacific Recent Past, Current & Future Analysis for Travel Vaccines by Disease Type - Influenza Vaccines, Diphtheria Vaccines, Hepatitis Vaccines and Typhoid & Other Vaccines - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 102: Asia-Pacific Historic Review for Travel Vaccines by Disease Type - Influenza Vaccines, Diphtheria Vaccines, Hepatitis Vaccines and Typhoid & Other Vaccines Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 103: Asia-Pacific 16-Year Perspective for Travel Vaccines by Disease Type - Percentage Breakdown of Value Sales for Influenza Vaccines, Diphtheria Vaccines, Hepatitis Vaccines and Typhoid & Other Vaccines for the Years 2014, 2025 & 2030
    • TABLE 104: Asia-Pacific Recent Past, Current & Future Analysis for Travel Vaccines by End-Use - Adult End-Use and Pediatric End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 105: Asia-Pacific Historic Review for Travel Vaccines by End-Use - Adult End-Use and Pediatric End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 106: Asia-Pacific 16-Year Perspective for Travel Vaccines by End-Use - Percentage Breakdown of Value Sales for Adult End-Use and Pediatric End-Use for the Years 2014, 2025 & 2030
  • AUSTRALIA
    • Travel Vaccines Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2025 (E)
    • TABLE 107: Australia Recent Past, Current & Future Analysis for Travel Vaccines by Disease Type - Influenza Vaccines, Diphtheria Vaccines, Hepatitis Vaccines and Typhoid & Other Vaccines - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 108: Australia Historic Review for Travel Vaccines by Disease Type - Influenza Vaccines, Diphtheria Vaccines, Hepatitis Vaccines and Typhoid & Other Vaccines Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 109: Australia 16-Year Perspective for Travel Vaccines by Disease Type - Percentage Breakdown of Value Sales for Influenza Vaccines, Diphtheria Vaccines, Hepatitis Vaccines and Typhoid & Other Vaccines for the Years 2014, 2025 & 2030
    • TABLE 110: Australia Recent Past, Current & Future Analysis for Travel Vaccines by End-Use - Adult End-Use and Pediatric End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 111: Australia Historic Review for Travel Vaccines by End-Use - Adult End-Use and Pediatric End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 112: Australia 16-Year Perspective for Travel Vaccines by End-Use - Percentage Breakdown of Value Sales for Adult End-Use and Pediatric End-Use for the Years 2014, 2025 & 2030
  • INDIA
    • Travel Vaccines Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2025 (E)
    • TABLE 113: India Recent Past, Current & Future Analysis for Travel Vaccines by Disease Type - Influenza Vaccines, Diphtheria Vaccines, Hepatitis Vaccines and Typhoid & Other Vaccines - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 114: India Historic Review for Travel Vaccines by Disease Type - Influenza Vaccines, Diphtheria Vaccines, Hepatitis Vaccines and Typhoid & Other Vaccines Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 115: India 16-Year Perspective for Travel Vaccines by Disease Type - Percentage Breakdown of Value Sales for Influenza Vaccines, Diphtheria Vaccines, Hepatitis Vaccines and Typhoid & Other Vaccines for the Years 2014, 2025 & 2030
    • TABLE 116: India Recent Past, Current & Future Analysis for Travel Vaccines by End-Use - Adult End-Use and Pediatric End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 117: India Historic Review for Travel Vaccines by End-Use - Adult End-Use and Pediatric End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 118: India 16-Year Perspective for Travel Vaccines by End-Use - Percentage Breakdown of Value Sales for Adult End-Use and Pediatric End-Use for the Years 2014, 2025 & 2030
  • SOUTH KOREA
    • TABLE 119: South Korea Recent Past, Current & Future Analysis for Travel Vaccines by Disease Type - Influenza Vaccines, Diphtheria Vaccines, Hepatitis Vaccines and Typhoid & Other Vaccines - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 120: South Korea Historic Review for Travel Vaccines by Disease Type - Influenza Vaccines, Diphtheria Vaccines, Hepatitis Vaccines and Typhoid & Other Vaccines Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 121: South Korea 16-Year Perspective for Travel Vaccines by Disease Type - Percentage Breakdown of Value Sales for Influenza Vaccines, Diphtheria Vaccines, Hepatitis Vaccines and Typhoid & Other Vaccines for the Years 2014, 2025 & 2030
    • TABLE 122: South Korea Recent Past, Current & Future Analysis for Travel Vaccines by End-Use - Adult End-Use and Pediatric End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 123: South Korea Historic Review for Travel Vaccines by End-Use - Adult End-Use and Pediatric End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 124: South Korea 16-Year Perspective for Travel Vaccines by End-Use - Percentage Breakdown of Value Sales for Adult End-Use and Pediatric End-Use for the Years 2014, 2025 & 2030
  • REST OF ASIA-PACIFIC
    • TABLE 125: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Travel Vaccines by Disease Type - Influenza Vaccines, Diphtheria Vaccines, Hepatitis Vaccines and Typhoid & Other Vaccines - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 126: Rest of Asia-Pacific Historic Review for Travel Vaccines by Disease Type - Influenza Vaccines, Diphtheria Vaccines, Hepatitis Vaccines and Typhoid & Other Vaccines Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 127: Rest of Asia-Pacific 16-Year Perspective for Travel Vaccines by Disease Type - Percentage Breakdown of Value Sales for Influenza Vaccines, Diphtheria Vaccines, Hepatitis Vaccines and Typhoid & Other Vaccines for the Years 2014, 2025 & 2030
    • TABLE 128: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Travel Vaccines by End-Use - Adult End-Use and Pediatric End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 129: Rest of Asia-Pacific Historic Review for Travel Vaccines by End-Use - Adult End-Use and Pediatric End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 130: Rest of Asia-Pacific 16-Year Perspective for Travel Vaccines by End-Use - Percentage Breakdown of Value Sales for Adult End-Use and Pediatric End-Use for the Years 2014, 2025 & 2030
  • LATIN AMERICA
    • Travel Vaccines Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2025 (E)
    • TABLE 131: Latin America Recent Past, Current & Future Analysis for Travel Vaccines by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 132: Latin America Historic Review for Travel Vaccines by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 133: Latin America 16-Year Perspective for Travel Vaccines by Geographic Region - Percentage Breakdown of Value Sales for Argentina, Brazil, Mexico and Rest of Latin America Markets for Years 2014, 2025 & 2030
    • TABLE 134: Latin America Recent Past, Current & Future Analysis for Travel Vaccines by Disease Type - Influenza Vaccines, Diphtheria Vaccines, Hepatitis Vaccines and Typhoid & Other Vaccines - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 135: Latin America Historic Review for Travel Vaccines by Disease Type - Influenza Vaccines, Diphtheria Vaccines, Hepatitis Vaccines and Typhoid & Other Vaccines Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 136: Latin America 16-Year Perspective for Travel Vaccines by Disease Type - Percentage Breakdown of Value Sales for Influenza Vaccines, Diphtheria Vaccines, Hepatitis Vaccines and Typhoid & Other Vaccines for the Years 2014, 2025 & 2030
    • TABLE 137: Latin America Recent Past, Current & Future Analysis for Travel Vaccines by End-Use - Adult End-Use and Pediatric End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 138: Latin America Historic Review for Travel Vaccines by End-Use - Adult End-Use and Pediatric End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 139: Latin America 16-Year Perspective for Travel Vaccines by End-Use - Percentage Breakdown of Value Sales for Adult End-Use and Pediatric End-Use for the Years 2014, 2025 & 2030
  • ARGENTINA
    • TABLE 140: Argentina Recent Past, Current & Future Analysis for Travel Vaccines by Disease Type - Influenza Vaccines, Diphtheria Vaccines, Hepatitis Vaccines and Typhoid & Other Vaccines - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 141: Argentina Historic Review for Travel Vaccines by Disease Type - Influenza Vaccines, Diphtheria Vaccines, Hepatitis Vaccines and Typhoid & Other Vaccines Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 142: Argentina 16-Year Perspective for Travel Vaccines by Disease Type - Percentage Breakdown of Value Sales for Influenza Vaccines, Diphtheria Vaccines, Hepatitis Vaccines and Typhoid & Other Vaccines for the Years 2014, 2025 & 2030
    • TABLE 143: Argentina Recent Past, Current & Future Analysis for Travel Vaccines by End-Use - Adult End-Use and Pediatric End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 144: Argentina Historic Review for Travel Vaccines by End-Use - Adult End-Use and Pediatric End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 145: Argentina 16-Year Perspective for Travel Vaccines by End-Use - Percentage Breakdown of Value Sales for Adult End-Use and Pediatric End-Use for the Years 2014, 2025 & 2030
  • BRAZIL
    • TABLE 146: Brazil Recent Past, Current & Future Analysis for Travel Vaccines by Disease Type - Influenza Vaccines, Diphtheria Vaccines, Hepatitis Vaccines and Typhoid & Other Vaccines - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 147: Brazil Historic Review for Travel Vaccines by Disease Type - Influenza Vaccines, Diphtheria Vaccines, Hepatitis Vaccines and Typhoid & Other Vaccines Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 148: Brazil 16-Year Perspective for Travel Vaccines by Disease Type - Percentage Breakdown of Value Sales for Influenza Vaccines, Diphtheria Vaccines, Hepatitis Vaccines and Typhoid & Other Vaccines for the Years 2014, 2025 & 2030
    • TABLE 149: Brazil Recent Past, Current & Future Analysis for Travel Vaccines by End-Use - Adult End-Use and Pediatric End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 150: Brazil Historic Review for Travel Vaccines by End-Use - Adult End-Use and Pediatric End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 151: Brazil 16-Year Perspective for Travel Vaccines by End-Use - Percentage Breakdown of Value Sales for Adult End-Use and Pediatric End-Use for the Years 2014, 2025 & 2030
  • MEXICO
    • TABLE 152: Mexico Recent Past, Current & Future Analysis for Travel Vaccines by Disease Type - Influenza Vaccines, Diphtheria Vaccines, Hepatitis Vaccines and Typhoid & Other Vaccines - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 153: Mexico Historic Review for Travel Vaccines by Disease Type - Influenza Vaccines, Diphtheria Vaccines, Hepatitis Vaccines and Typhoid & Other Vaccines Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 154: Mexico 16-Year Perspective for Travel Vaccines by Disease Type - Percentage Breakdown of Value Sales for Influenza Vaccines, Diphtheria Vaccines, Hepatitis Vaccines and Typhoid & Other Vaccines for the Years 2014, 2025 & 2030
    • TABLE 155: Mexico Recent Past, Current & Future Analysis for Travel Vaccines by End-Use - Adult End-Use and Pediatric End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 156: Mexico Historic Review for Travel Vaccines by End-Use - Adult End-Use and Pediatric End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 157: Mexico 16-Year Perspective for Travel Vaccines by End-Use - Percentage Breakdown of Value Sales for Adult End-Use and Pediatric End-Use for the Years 2014, 2025 & 2030
  • REST OF LATIN AMERICA
    • TABLE 158: Rest of Latin America Recent Past, Current & Future Analysis for Travel Vaccines by Disease Type - Influenza Vaccines, Diphtheria Vaccines, Hepatitis Vaccines and Typhoid & Other Vaccines - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 159: Rest of Latin America Historic Review for Travel Vaccines by Disease Type - Influenza Vaccines, Diphtheria Vaccines, Hepatitis Vaccines and Typhoid & Other Vaccines Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 160: Rest of Latin America 16-Year Perspective for Travel Vaccines by Disease Type - Percentage Breakdown of Value Sales for Influenza Vaccines, Diphtheria Vaccines, Hepatitis Vaccines and Typhoid & Other Vaccines for the Years 2014, 2025 & 2030
    • TABLE 161: Rest of Latin America Recent Past, Current & Future Analysis for Travel Vaccines by End-Use - Adult End-Use and Pediatric End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 162: Rest of Latin America Historic Review for Travel Vaccines by End-Use - Adult End-Use and Pediatric End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 163: Rest of Latin America 16-Year Perspective for Travel Vaccines by End-Use - Percentage Breakdown of Value Sales for Adult End-Use and Pediatric End-Use for the Years 2014, 2025 & 2030
  • MIDDLE EAST
    • Travel Vaccines Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2025 (E)
    • TABLE 164: Middle East Recent Past, Current & Future Analysis for Travel Vaccines by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 165: Middle East Historic Review for Travel Vaccines by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 166: Middle East 16-Year Perspective for Travel Vaccines by Geographic Region - Percentage Breakdown of Value Sales for Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets for Years 2014, 2025 & 2030
    • TABLE 167: Middle East Recent Past, Current & Future Analysis for Travel Vaccines by Disease Type - Influenza Vaccines, Diphtheria Vaccines, Hepatitis Vaccines and Typhoid & Other Vaccines - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 168: Middle East Historic Review for Travel Vaccines by Disease Type - Influenza Vaccines, Diphtheria Vaccines, Hepatitis Vaccines and Typhoid & Other Vaccines Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 169: Middle East 16-Year Perspective for Travel Vaccines by Disease Type - Percentage Breakdown of Value Sales for Influenza Vaccines, Diphtheria Vaccines, Hepatitis Vaccines and Typhoid & Other Vaccines for the Years 2014, 2025 & 2030
    • TABLE 170: Middle East Recent Past, Current & Future Analysis for Travel Vaccines by End-Use - Adult End-Use and Pediatric End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 171: Middle East Historic Review for Travel Vaccines by End-Use - Adult End-Use and Pediatric End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 172: Middle East 16-Year Perspective for Travel Vaccines by End-Use - Percentage Breakdown of Value Sales for Adult End-Use and Pediatric End-Use for the Years 2014, 2025 & 2030
  • IRAN
    • TABLE 173: Iran Recent Past, Current & Future Analysis for Travel Vaccines by Disease Type - Influenza Vaccines, Diphtheria Vaccines, Hepatitis Vaccines and Typhoid & Other Vaccines - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 174: Iran Historic Review for Travel Vaccines by Disease Type - Influenza Vaccines, Diphtheria Vaccines, Hepatitis Vaccines and Typhoid & Other Vaccines Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 175: Iran 16-Year Perspective for Travel Vaccines by Disease Type - Percentage Breakdown of Value Sales for Influenza Vaccines, Diphtheria Vaccines, Hepatitis Vaccines and Typhoid & Other Vaccines for the Years 2014, 2025 & 2030
    • TABLE 176: Iran Recent Past, Current & Future Analysis for Travel Vaccines by End-Use - Adult End-Use and Pediatric End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 177: Iran Historic Review for Travel Vaccines by End-Use - Adult End-Use and Pediatric End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 178: Iran 16-Year Perspective for Travel Vaccines by End-Use - Percentage Breakdown of Value Sales for Adult End-Use and Pediatric End-Use for the Years 2014, 2025 & 2030
  • ISRAEL
    • TABLE 179: Israel Recent Past, Current & Future Analysis for Travel Vaccines by Disease Type - Influenza Vaccines, Diphtheria Vaccines, Hepatitis Vaccines and Typhoid & Other Vaccines - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 180: Israel Historic Review for Travel Vaccines by Disease Type - Influenza Vaccines, Diphtheria Vaccines, Hepatitis Vaccines and Typhoid & Other Vaccines Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 181: Israel 16-Year Perspective for Travel Vaccines by Disease Type - Percentage Breakdown of Value Sales for Influenza Vaccines, Diphtheria Vaccines, Hepatitis Vaccines and Typhoid & Other Vaccines for the Years 2014, 2025 & 2030
    • TABLE 182: Israel Recent Past, Current & Future Analysis for Travel Vaccines by End-Use - Adult End-Use and Pediatric End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 183: Israel Historic Review for Travel Vaccines by End-Use - Adult End-Use and Pediatric End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 184: Israel 16-Year Perspective for Travel Vaccines by End-Use - Percentage Breakdown of Value Sales for Adult End-Use and Pediatric End-Use for the Years 2014, 2025 & 2030
  • SAUDI ARABIA
    • TABLE 185: Saudi Arabia Recent Past, Current & Future Analysis for Travel Vaccines by Disease Type - Influenza Vaccines, Diphtheria Vaccines, Hepatitis Vaccines and Typhoid & Other Vaccines - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 186: Saudi Arabia Historic Review for Travel Vaccines by Disease Type - Influenza Vaccines, Diphtheria Vaccines, Hepatitis Vaccines and Typhoid & Other Vaccines Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 187: Saudi Arabia 16-Year Perspective for Travel Vaccines by Disease Type - Percentage Breakdown of Value Sales for Influenza Vaccines, Diphtheria Vaccines, Hepatitis Vaccines and Typhoid & Other Vaccines for the Years 2014, 2025 & 2030
    • TABLE 188: Saudi Arabia Recent Past, Current & Future Analysis for Travel Vaccines by End-Use - Adult End-Use and Pediatric End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 189: Saudi Arabia Historic Review for Travel Vaccines by End-Use - Adult End-Use and Pediatric End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 190: Saudi Arabia 16-Year Perspective for Travel Vaccines by End-Use - Percentage Breakdown of Value Sales for Adult End-Use and Pediatric End-Use for the Years 2014, 2025 & 2030
  • UNITED ARAB EMIRATES
    • TABLE 191: UAE Recent Past, Current & Future Analysis for Travel Vaccines by Disease Type - Influenza Vaccines, Diphtheria Vaccines, Hepatitis Vaccines and Typhoid & Other Vaccines - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 192: UAE Historic Review for Travel Vaccines by Disease Type - Influenza Vaccines, Diphtheria Vaccines, Hepatitis Vaccines and Typhoid & Other Vaccines Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 193: UAE 16-Year Perspective for Travel Vaccines by Disease Type - Percentage Breakdown of Value Sales for Influenza Vaccines, Diphtheria Vaccines, Hepatitis Vaccines and Typhoid & Other Vaccines for the Years 2014, 2025 & 2030
    • TABLE 194: UAE Recent Past, Current & Future Analysis for Travel Vaccines by End-Use - Adult End-Use and Pediatric End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 195: UAE Historic Review for Travel Vaccines by End-Use - Adult End-Use and Pediatric End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 196: UAE 16-Year Perspective for Travel Vaccines by End-Use - Percentage Breakdown of Value Sales for Adult End-Use and Pediatric End-Use for the Years 2014, 2025 & 2030
  • REST OF MIDDLE EAST
    • TABLE 197: Rest of Middle East Recent Past, Current & Future Analysis for Travel Vaccines by Disease Type - Influenza Vaccines, Diphtheria Vaccines, Hepatitis Vaccines and Typhoid & Other Vaccines - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 198: Rest of Middle East Historic Review for Travel Vaccines by Disease Type - Influenza Vaccines, Diphtheria Vaccines, Hepatitis Vaccines and Typhoid & Other Vaccines Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 199: Rest of Middle East 16-Year Perspective for Travel Vaccines by Disease Type - Percentage Breakdown of Value Sales for Influenza Vaccines, Diphtheria Vaccines, Hepatitis Vaccines and Typhoid & Other Vaccines for the Years 2014, 2025 & 2030
    • TABLE 200: Rest of Middle East Recent Past, Current & Future Analysis for Travel Vaccines by End-Use - Adult End-Use and Pediatric End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 201: Rest of Middle East Historic Review for Travel Vaccines by End-Use - Adult End-Use and Pediatric End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 202: Rest of Middle East 16-Year Perspective for Travel Vaccines by End-Use - Percentage Breakdown of Value Sales for Adult End-Use and Pediatric End-Use for the Years 2014, 2025 & 2030
  • AFRICA
    • Travel Vaccines Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2025 (E)
    • TABLE 203: Africa Recent Past, Current & Future Analysis for Travel Vaccines by Disease Type - Influenza Vaccines, Diphtheria Vaccines, Hepatitis Vaccines and Typhoid & Other Vaccines - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 204: Africa Historic Review for Travel Vaccines by Disease Type - Influenza Vaccines, Diphtheria Vaccines, Hepatitis Vaccines and Typhoid & Other Vaccines Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 205: Africa 16-Year Perspective for Travel Vaccines by Disease Type - Percentage Breakdown of Value Sales for Influenza Vaccines, Diphtheria Vaccines, Hepatitis Vaccines and Typhoid & Other Vaccines for the Years 2014, 2025 & 2030
    • TABLE 206: Africa Recent Past, Current & Future Analysis for Travel Vaccines by End-Use - Adult End-Use and Pediatric End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 207: Africa Historic Review for Travel Vaccines by End-Use - Adult End-Use and Pediatric End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 208: Africa 16-Year Perspective for Travel Vaccines by End-Use - Percentage Breakdown of Value Sales for Adult End-Use and Pediatric End-Use for the Years 2014, 2025 & 2030

IV. COMPETITION

샘플 요청 목록
0 건의 상품을 선택 중
목록 보기
전체삭제